Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Fig. 2

Circulating ESR1 mutation frequency during HR+ breast cancer history. At the end of adjuvant treatment by AI, circulating ESR1 mutations were not detected among the 42 patients of this cohort. At relapse, 2/38 patients (5.3%) had a detectable circulating ESR1 mutation. At progression after re-exposure to AI as first-line metastatic treatment, 7/21 patients (33%) had a detectable circulating ESR1 mutation. AI aromatase inhibitor, CT chemotherapy, RT radiation therapy

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us